OSLI Retina

May 2020 Supplement

Issue link: http://osliretina.healio.com/i/1250748

Contents of this Issue


Page 1 of 43

Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated®, and is an official publication of ARVO/ISIE. Publication Office: SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated®, 2020. All rights reserved. No part of this publication may be reproduced without prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $228, electronic only: $203. Institutional: One year—$719. Residents and fellows: $107 for one year (a letter of certification indicating residency of the subscriber is re- quired). Canada add 5% GST, all other countries add $58 per year. All subscriptions, without exception, will start with the first issue published after the order is received. Single copies and back issues, when available, are $96. Payment must accompany order. Subscription requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to replace ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina®, SLACK Incorporated®, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated®. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated®. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclo- sures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEngineering Abstracts, CAB Abstracts, and SCOPUS. Follow OSLIJournal OSLI Retina SLACK Incorporated 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-848-1000 Email: osli@healio.com Healio.com/OSLIRetina SLACK I N C O R P O R A T E D ® SLACK Incorporated Chief Content Officer Joan-Marie Stiglich, ELS EDITORIAL Senior Editorial Director David W. Mullin Executive Editor Cara Dickinson Production and Circulation Director Cheryl McKeown Production Associate Ryan Davis HEALIO STRATEGIC SOLUTIONS Vice President Chris Rosenberg Senior Project Manager Darryl Saull Project Coordinator Meghan E. McDonald Medical Copy Editor Norma Hanna, ELS SALES Group Sales Director, Eye Care Scott Wright National Account Manager Laura Renna Director, Sales Administration and Support Carolyn Boerner Sales Administrator Wanda Granato Sales Coordinator, Recruitment Jennifer Carroll Director of Audience Development Stephanie McHugh Reprints/Eprints Licensing Opportunities: The Sheridan Press 800-635-7181 ext. 8065 DESIGN Creative Director Thomas Cavallaro The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Senior Vice President Denise Mealey Chief Technology Officer Linda Baker Celebrating the research and accomplishments of residents, fellows, and medical students is the goal of the Retina Research Scholar Honoree Program. Now in its third year, the program has expanded with a record number of applicants. Probably most rewarding is to see that students and institutions value the scientific rigor of the program. When I reviewed applica- tions for residency and fellowship this year, I saw awardees of the Retina Research Scholar Honoree Program list it on their resumes, fulfilling one of the goals of this program. Residents, fellows, and students fuel the engine for scientific progress. They ask bold questions and seek answers. How do we characterize the maculopathy associ- ated with osmotic blood–brain barrier disruption and chemotherapy in patients with primary central nervous system lymphoma? What is the prevalence of retinal diseases and associated risk factors in an African population? What is the 20-year incidence of macular telangiectasia type 2 and associated systemic comorbidities? And what are the genotypic and phenotypic antibiotic resistance patterns in Staphylococcus epidermidis endophthalmitis? These are some of the many questions asked in the 2019 Retina Research Scholar Honoree Program. The aim of this program is to celebrate their research accomplish- ments, expose them to their peers who are also contributing to the field, and to recog- nize truly exceptional research. Of the many presentations received, only a select few made it to the oral presentation symposium held just before the American Academy of Ophthalmology 2019 Annual Meeting in San Francisco. In this supplement, we highlight five of these presentations. This program would not be possible without support from an educational grant from Regeneron Pharmaceuticals. On behalf of the judging committee for the Retina Research Scholar Honoree Program, I would like to congratulate all participants. We look forward to the presentations in 2020. Rishi P. Singh, MD Cole Eye Institute Cleveland Clinic Foundation Associate Editor, OSLI Retina doi: 10.3928/23258160-20200113-01 Research Developments in the Treatment of Retinal Disease: Finalists From the 3rd Annual Retina Research Scholar Honoree Program

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - May 2020 Supplement